KALA BIO, Inc. (KALA)
| Market Cap | 16.73M -72.2% |
| Revenue (ttm) | n/a |
| Net Income | -19.65M |
| EPS | -6.34 |
| Shares Out | 18.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,591 |
| Open | 0.9349 |
| Previous Close | 0.8987 |
| Day's Range | 0.8900 - 0.9399 |
| 52-Week Range | 0.5900 - 1,030.0000 |
| Beta | -2.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About KALA
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agent... [Read more]
Financial Performance
Financial StatementsNews
KALA BIO Quarterly report: Q2 2026
KALA BIO has published its Q2 2026 quarterly earnings report on August 19, 2026.
KALA BIO Registration statement: Registration filing
KALA BIO filed a registration statement on June 12, 2026, providing details about a securities offering with the SEC.
KALA BIO Quarterly report: Q1 2026
KALA BIO has published its Q1 2026 quarterly earnings report on May 15, 2026.
Kala Bio falls -21.7%
Kala Bio (KALA) is down -21.7%, or -85c to $3.06.
Kala Bio files $350M mixed securities shelf
17:27 EDT Kala Bio (KALA) files $350M mixed securities shelf
Kala Bio announces reverse stock split
Kala Bio (KALA) announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The…
KALA BIO Announces Reverse Stock Split
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par...
KALA BIO Registration statement: Registration filing
KALA BIO filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine
KALA BIO (KALA) “celebrated the landmark Executive Order” signed by U.S. President Donald Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds,…
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
KALA BIO Annual report: Q4 2025
KALA BIO has published its Q4 2025 annual report on April 15, 2026.
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, develop...
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Genera...
Red Light Holland engages Kala Bio with its Researgency.ai platform
Red Light Holland and Kala Bio (KALA) announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support…
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO ...
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto,...
Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents
Open-source breakthrough demonstrates AI agents can run 100+ experiments overnight-reinforcing the agentic R&D paradigm Researgency.ai is bringing to life sciences with Kala Bio (KALA) Toronto, Ontari...
Kala Bio poised to ship first commercial AI product in about 14 days
Kala Bio (KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the company from a clinical-stage biotech into a dual-engine growth…
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to ...
Kala Bio announces initiative to build AI infrastructure platform
Kala Bio (KALA) announced a strategic initiative to build a biotechnology industry dedicated, on-premises artificial intelligence infrastructure platform, designed to be deployed directly within biote...
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”), a clinical-stage biopharmaceutical company, today announced a strategic initiative to buil...
KALA BIO Registration statement: Registration Filing
KALA BIO filed a registration statement on February 10, 2026, providing details about a securities offering with the SEC.
Kala Bio files to sell 241.44M shares of common stock for holders
06:14 EST Kala Bio (KALA) files to sell 241.44M shares of common stock for holders
KALA BIO Transcript: AGM 2026
The meeting covered seven proposals, including director elections, executive compensation, auditor ratification, stock issuance, share increase, and a potential reverse split. All proposals passed by majority vote, and no questions were raised by stockholders.
KALA BIO Proxy statement: Proxy Filing
KALA BIO filed a proxy statement on January 26, 2026, providing details for shareholder voting and corporate governance matters.